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Multiple-Breath Washout as a Lung Function Test in Cystic Fibrosis: A Cystic Fibrosis Foundation 
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Abstract  
The lung clearance index (LCI) is a lung function parameter derived from the multiple-breath washout 
(MBW) test. Although first developed 60 years ago, the technique was not widely used for many years. 
Recent technological advances in equipment design have produced gains in popularity for this test among 
cystic fibrosis (CF) researchers and clinicians, particularly for testing preschool-aged children. LCI has 
been shown to be feasible and sensitive to early CF lung disease in patients of all ages from infancy to 
adulthood. A workshop was convened in January 2014 by the North American Cystic Fibrosis Foundation 
to determine the readiness of the LCI for use in multicenter clinical trials as well as clinical care. The 
workshop concluded that the MBW text is a valuable potential outcome measure for CF clinical trials in 
preschool-aged patients and in older patients with FEV^sub 1^ in the normal range. However, gaps in 
knowledge about the choice of device, gas, and standardization across systems are key issues precluding 
its use as a clinical trial end point in infants. Based on the current evidence, there are insufficient data to 
support the use of LCI or MBW parameters in the routine clinical management of patients with CF.  
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Cystic fibrosis (CF) airway disease is characterized by airway surface liquid depletion, mucus 
plugging, and chronic infection and inflammation resulting in bronchiectasis. Although progressive 
airway obstruction as detected by spirometry is typical of CF, advances in multidisciplinary care over the 
last 2 decades have resulted in preservation of spirometric lung function within the normal range into 
young adulthood (1, 2). In contrast, there is mounting evidence that progression of bronchiectasis can go 
undetected by spirometry for many years (3, 4). Objective evaluation of lung function in early CF lung 
disease has been hampered by a lack of feasible sensitive outcome measures. On the other hand, early 
intervention before onset of irreversible lung damage requires assessment of infants and preschool 
children. The challenge is to find a feasible sensitive objective outcome measure to assess new 
interventions applied across all age groups.  
Recently, an American Thoracic Society workshop report reviewed the literature supporting the 
use of preschool lung function tests in the diagnosis and monitoring of preschool lung disease, including 
CF (5). This report highlighted multiple-breath washout (MBW) for its ability to discriminate between 
health and disease in preschool children with CF and its potential use for monitoring preschool lung 
disease.  
Due to the heightened interest in this lung function test for CF from both the clinical and research 
communities, the North American Cystic Fibrosis Foundation (CFF) and Therapeutics Development 
Network (TDN) hosted a workshop that brought together international leaders in the field to discuss the 
level of evidence and challenges in moving this outcome measure into clinical trials and practice. To 
better understand the degree of uptake of this new technology, a survey of the CF clinic directors was 
performed. Based on the survey and the goals of the workshop; this report was produced to give guidance 
to the North American CF community on the readiness of this tool for clinical trials and current 
limitations in knowledge that must be addressed before recommending implementation of this technology 
into clinical practice.  
The workshop report is the cumulative efforts of all participants. Each of the participants was a 
member of one of the six working group based on their expertise. Each working group presented a 
summary of available evidence for their topic at the meeting. After the meeting, each group submitted a 
draft of their section for inclusion in the final report. The Chair (P.S.) and Co-Chairs (C.M., W.M.) of the 
workshop summarized the findings into an overall workshop report with extensive input from all 
participants. The final manuscript was approved by all workshop participants.  
MBW Testing  
An old technology that has been recently revisited, the MBW test is a gas washout technique. The 
technique was introduced by Ward S. Fowler in 1952. He described a method to measure nitrogen 
clearance curves of single breaths in healthy subjects and those with cardiorespiratory disease to quantify 
the "unevenness of gas distribution" (6). With advances in gas analyzers and computers to faster 
integration of gas and volume signals, the MBW method has been refined to allow the measurement of 
ventilation distribution and gas clearance curves during tidal breaths, thus permitting its use in very young 
patients. A recent American Thoracic Society/European Respiratory Society consensus statement was 
published on the measurement of MBW (7).  
In any washout test, there is a wash-in and a washout phase. For inert extrinsic gases (i.e., sulfur 
hexafluoride, SF6; helium, He) or nonresident pulmonary gases, during the wash-in phase the test gas is 
delivered at a known concentration. Wash-in is complete when the expired gas concentration reaches the 
delivered gas concentration. For inert intrinsic gases (i.e., nitrogen, N2), no formal wash-in phase is 
required, and a few tidal breaths are measured to ensure that the measured resident N2 is stable (normally 
at 80%).  
The two most commonly reported parameters from MBW tests are the lung clearance index (LCI) 
and moment ratios (MRs). Measurements of LCI and MR are taken during the washout period. During the 
washout phase, subjects inhale gases that do not contain the test gas of interest (i.e., room air for SF6 and 
100% oxygen for N2). The principles of the washout are the same regardless of the test gas measured. 
The washout is stopped once the test gas reaches 1/40 of the initial gas concentration (Figure 1).  
The LCI  
The lung clearance index is a marker of overall lung ventilation inhomogeneity at the point that 
1/40 of the concentration of the test gas remains in the exhaled breath. It is calculated as the number of 
lung volume turnovers required to clear the lung of the inert gas. Lung volume turnovers reflect the FRC, 
which is measured during the washout test.  
The two parameters are calculated as follows:  
FRC = net  volume  of  the  inert 
gas  exhaled(CETstart – CEtend) 
LCI = VCE/FRC 
where CET is the end-tidal concentration of the gas measured at the start (CETstart) and end (CETend) of 
the washout. VCE is the cumulative net expired volume to reach 1/40 of the initial gas concentration (sum 
of tidal breath volumes minus the apparatus dead space) during the washout.  
Thus, as lung ventilation worsens, the number of tidal breaths and expired volumes required to 
wash out the inert gas results in an increasing LCI value.  
Moment Ratios  
MRs are used to quantify the ventilation inhomogeneity present and are described in detail 
elsewhere (7-9). Calculation of MRs is more challenging, but it holds the potential advantage of 
describing the entire washout curve rather than LCI, which assesses one time point (final cumulative 
expired volume at 1/40 starting gas concentration). MRs calculate the area under the washout curve with 
emphasis on the inert gas release during latter portions of the washout curve, which represent delayed 
emptying. The curves generated by MR analysis are independent of changes in breathing frequency and 
VT. This parameter has not been commonly reported in clinical trials and as such is not a focus of the 
current document, but it remains an area of research interest.  
MBW Technical Considerations  
Inert gas washout tests were described 60 years ago. Practical application required a series of 
important developments, including fast-responding inert gas analyzers, faster personal computers to 
process changes within breath, and standardization of test performance to produce robust accurate results. 
An international consensus statement (7) was published in early 2013 to guide both manufacturers and 
researchers in this technique. Standardization work is an ongoing process and is by no means complete. 
Available commercial devices are at different stages of development with respect to: degree of 
measurement validation, current suitability for different age ranges, affordability, regional regulatory 
agency approvals, and transparency of outcome (index) calculation (Table 1). There is no single device 
suitable for use across the entire pediatric and adult age range to date.  
The choice of tracer gas used is a key factor in selection of an MBW device. The most widely 
used inert gases are N2 and SF6. N2 MBW requires only 100% oxygen (O2) during the washout phase, 
which is readily available but may not be appropriate for use in infants due to effects of pure oxygen on 
tidal breathing parameters (10-12). Furthermore, the contribution of tissue N2 diffusion to washout 
characteristics, although believed to be negligible in healthy individuals, has not been rigorously studied. 
Although SF6 MBW seems physiologically preferable for use across all ages, critical issues preventing its 
continued use include cost and limited availability. Furthermore, SF6 was listed in the Kyoto protocol as 
one of the top six gases whose release should be limited (13); given that it is "the most potent greenhouse 
gas known" (14), its future continued sustained use is not feasible. N2 is becoming more widespread and 
is being used for all age groups except infants.  
Recent standardization work in device development and close collaboration between experienced 
operators suggest that previously reported between-center differences (15) may be avoidable with the use 
of commercial MBW equipment (16, 17). Furthermore, efforts to standardize not only commercial 
equipment but also patient interfaces (face mask, tubing, etc.) are important features to optimize and 
standardize measurement conditions. The current status of different commercially available equipment is 
summarized in Table 1.  
Currently, there are few commercially available licensed systems available to measure LCI in 
infants and young children. Furthermore, very few data are available comparing the measurements 
between systems and the algorithms used to calculate measurements. Measurements using different inert 
gases are not interchangeable, and their relationship in health and disease is different. For these reasons, 
normative data generated from one system should not be used for other devices. Thus, validation of 
equipment in young children and normative data for all age groups are key priority areas.  
MBW Measurement Considerations  
Quality control is an essential component during testing and during post testing analysis. Recent 
work has produced the first in-depth standard operating procedure for a commercial MBW device. The 
current focus of the working groups within the MBW community is to produce standard operating 
procedures for validated commercial devices as they become available to aid in the transition toward 
more routine research and clinical use. Here we highlight key features affecting feasibility and quality 
control during MBW testing.  
Test Duration  
The duration of the MBW test is a key determinant of feasibility in clinical practice and 
interventional trials. Although MBW is a passive tidal breathing test, the length of time to perform one 
test takes longer than conventional lung function tests (on average, 2-5 min per maneuver in a healthy 
subject, but longer in subjects with airway obstruction).  
The duration of MBW tests is determined in part by the number of trials that are performed and 
the cutoff values used for the lung clearance index.  
Number of Trials  
MBW is performed during tidal breathing; thus, criteria defining the "best attempt" are difficult to 
establish. For example, it is not known whether the lowest LCI reflects the most reliable MBW test. 
Currently, MBW analysis requires post hoc quality control assessment. Current standards require three 
repeatable tests after post hoc analysis, yet studies comparing the first two acceptable tests to this standard 
showed that the LCI value produced had comparable discriminative ability (18, 19). The impact of such a 
shortened protocol on research quality data for sensitivity to detect treatment responses is unknown.  
Lung Clearance Index Cutoff Values  
Recommendations to perform MBW tracer gas washout to 1/40 (2.5%) of the starting gas 
concentration are historically based on poor N2 sensor resolution and estimated N2 tissue contribution. 
One recent study showed that LCI from N2 MBW until 1/20 (5%) compared with LCI from standard 
MBW until 1/40 provided the same discriminative capacity between control subjects and children with 
CF (18). Total washout duration was abbreviated, and intratest variability was lower. Abbreviated MBW 
protocols potentially improve success rates, especially in patients with severe lung disease or patients 
with brief attention spans (20-22). However, there is a decrease in sensitivity to detect treatment 
differences associated with these abbreviated MBW protocol LCIs (23).  
Effect of Dead Space  
Currently, most studies in preschool children and infants have used respiratory mass 
spectrometers as gas analyzers for two reasons: (1) they allow sufficient gas sampling rates to allow for 
reliable gas concentration measurements in small VT at higher respiratory rates, and (2) they have limited 
equipment dead space across all age groups (from infancy to adulthood).  
Differences have been noted between respiratory mass spectrometer-based SF6 and commercial 
N2-based LCI measurements. N2 LCI measurements are reported as systematically higher than SF6-
based mass spectrometer-based LCI measurements (24). These differences are larger in preschool 
children than older children and adults, appear to be due to the higher VD/VT ratio associated with N2 
MBW equipment, and were independent of health status (patient with CF vs. healthy control subject) 
(25). Thus, every effort should be made to minimize equipment dead space in MBW systems.  
Analysis of MBW Test Results  
Offline data analysis using custom-made software has initially been used for MBW testing. This 
procedure is time consuming and would limit the clinical usefulness of these tests in a busy outpatient 
clinic. Further work is required to assess the impact of different software algorithms on MBW measures. 
This is especially relevant for preschool children, for whom nonuniform tidal breaths, small leaks, and 
other test artifacts (swallowing, talking, etc.) are an issue, and in infants, for whom rapid respiratory rates 
and smaller tidal breaths associated with sleep state can affect LCI measurements.  
Use of MRs as an Alternative to Lung Clearance Ratios for Early Detection of Lung Disease  
Compared with LCI, several other methods exist to mathematically describe the shape of the 
MBW washout curve. MR quantifies the area under the washout curve and has been shown to be sensitive 
in detecting CF lung disease (26, 27). Furthermore, MR seems to better reflect structural changes in 
infants with CF than LCI (28). Preliminary data suggest that MR tracks pulmonary function response to 
short-term interventions similarly to LCI and may be superior in detecting treatment effects for shortened 
washout period (23).  
Normal Value Reference Data  
Normative data generated from one system cannot be applied across other devices. Limited 
reference data are available and are device and gas specific(29,30).LCI declines through infancy and early 
childhood, remains constant in early childhood to adulthood, and slowly increases in the elderly (29, 31). 
Age is an important predictor of other MBW indices (e.g., concentration-normalized phase III slope 
analysis indices, Scond and Sacin). These data taken together suggest that raw values will not be useful in 
pediatrics and thus must be converted to z-scores to aid in longitudinal data interpretation.  
Gaps in Knowledge and Key Priority Areas for the Further Development of Measurement 
Techniques  
Multiple technical issues still need to be clarified, especially in infants and preschool children. 
Device-specific reference data are required throughout all age groups. Key issues related to data analysis 
include standardization and validation of the online software quality control.  
Usefulness of Lung Clearance Index: Evidence from Clinical Studies  
Evidence supporting the usefulness of the LCI has derived from both observational studies and clinical 
trials.  
Observational Studies  
LCI Correlation with Other Pulmonary Parameters  
The majority of studies performed in subjects with CF are cross-sectional, where LCI is related to 
other measures of lung function (26, 32), imaging (28, 33-35), or clinical status (36-38). These studies 
consistently demonstrate that, compared with healthy control subjects, LCI is abnormal in a significant 
proportion of preschool children with CF and in the majority of school-aged children and adults (32, 33, 
35, 39).  
In contrast to older groups, at least half of infants with CF have normal LCI (28, 40-42). 
Specifically, some infants appear to have normal LCI in the presence of abnormal infant spirometry 
(measured by the raised volume rapid thoracoabdominal compression technique) (40) or abnormal 
computed tomography (28). A multicenter study from London (43), tracking children from preschool 
years to early school age, demonstrated (1)that LCI is far more likely to be abnormal than spirometry in 
preschool years, and (2) abnormal LCI in preschool children predicts both abnormal LCI and abnormal 
spirometry during school-age years.  
Change in LCI with Microbiological Status  
Cross-sectional data in infants and children suggest that those with evidence of bacterial infection 
are more likely to have abnormal LCI (36, 38, 40). In a preschool cross sectional study, children who had 
"ever cultured" Pseudomonas aeruginosa from airway secretions had higher LCI than those who had not 
(32). Repeated measures within the Australian Respiratory Early Surveillance Team for Cystic Fibrosis 
(AREST CF) study suggest that LCI increases more in infants with airway infection than in those without 
infection (44).  
LCI Change in Relation to Clinical Status  
Among school-aged children, high LCI is consistently associated with increasing abnormality 
seen on chest CT, and this association has been demonstrated from infancy, through school age, to 
adulthood (28, 33-35). Increased LCI appears to predict those individuals who are more likely to have 
pulmonary exacerbations associated with infection (37), and LCI decreases when exacerbations are 
treated (45, 46).  
Clinical Trials  
The European CF Society Clinical Trial Network Standardization Committee has recently 
published a consensus document (47), which concludes that LCI has attractive features for its use in 
clinical trials involving young children and patients with mild lung disease. This assessment is based on 
several single-center and multicenter studies.  
To date, one single-center study examined the usefulness of LCI (measured by respiratory mass 
spectrometry) in an interventional study in infants and preschool children (50). This add-on pilot study to 
the Infant Study of Inhaled Saline (ISIS) in CF trial (51) attempted MBW measurements in all 27 infant 
and preschool subjects participating in the Toronto center. Successful paired MBW measurements at 
baseline and end of therapy were obtained in 93% of participants. A significant treatment effect of 
hypertonic saline compared with isotonic saline was detected using LCI after adjustment for height. 
However, the pattern of LCI change with treatment differed between infants and preschool children. In 
preschool children, LCI was abnormal at baseline and improved with hypertonic saline treatment, 
whereas in infants, LCI was in the normal range at baseline and remained in the normal range after 
treatment with hypertonic saline. These different patterns of change in LCI have implications for sample 
size calculations for studies using LCI as an outcome measure for these different age groups.  
Two randomized double-blind placebo-controlled single-center studies using an SF6 respiratory 
mass spectrometer have assessed the responsiveness of LCI in school-aged children with CF with normal 
spirometry measures. LCI improved after treatment with hypertonic saline (48) and with dornase alfa (49) 
over a 1-month period. Notably, FEV1 did not detect a treatment effect in these studies.  
One multicenter interventional study enrolled patients, older than 8 years, with at least one copy 
of the G551D mutation and normal FEV1 (above 90% predicted at baseline) and assessed the ability of 
LCI to detect a treatment effect of ivacaftor (52). The magnitude of the treatment effect detected in this 
group of patients was twice as high when compared with the hypertonic saline and dornase alfa studies 
and provided evidence that LCI could be a responsive alternative outcome for pulmonary abnormalities in 
patients with mild lung disease. Notably, this study included centers with no previous experience in 
MBW measurements and implemented a training and qualification strategy that ensured high-quality data 
for the clinical trial. This type of strategy will be important to implement for future trials.  
Gaps in Knowledge and Key Priority Areas for Future Clinical Studies  
The majority of the observational studies cited above are cross-sectional studies. Given that more 
recent cohorts of young children with CF have less severe lung disease than those of a decade ago, 
previous observational studies may not provide valid predictions about change in LCI for current age 
groups. Longitudinal studies in health and disease are required to clarify, how LCI changes over time in 
CF.  
Interventional studies to date have been performed with methodology that is not commercially 
available. Although these studies have found LCI sensitive at detecting a treatment effect, it is still 
unclear what magnitude of effect could be considered as clinically relevant. Also, no long-term 
interventional study with LCI as an outcome measure has been conducted to assess the sustainability of 
effects seen in shorter-term trials. Finally, it is unclear if noted improvements in LCI have predictive 
capacity for other known surrogate outcome factors for CF health status, such as rate of decline in FEV1 
or pulmonary exacerbation rate.  
Future work should focus on:  
1. Delineating the short-term and longer term repeatability of LCI from commercial devices.  
2. Establishing the feasibility of performing MBW measurements in multicenter studies that 
include centers with limited experience.  
3. Establishing a minimal clinical important difference for clinical trial outcomes.  
4. Evaluating the role of LCI in interventional studies including patients with an FEV1 below the 
normal range  
MBW Testing in the Clinical Setting  
In an attempt to assess the current level of uptake and interest for LCI in the CF community and 
interest in the technology, a questionnaire was sent to all CF centers across the United States, Canada, and 
Europe. Eighty-four responses were received, of which 54 were from the United States, 6 from Canada, 
and 24 from Europe. Of these 84 centers, 31 (38%) are currently performing measurements of LCI, of 
which 21 reported its use primarily for research.  
When asked "what were the most important issues to be considered prior to bringing this test into 
clinical practice," 50% of the respondents cited a lack of evidence to support its role in clinical decision 
making as the most important issue. This was followed by: a need for a clinical practice guideline for 
interpretation, standardized training program for testing, and finally the generation of normative data.  
Current Experience with Clinical Use of the LCI  
To date, MBW is not a routine clinical test in U.S. and Canadian CF clinics. Many devices are not 
Food and Drug Administration approved, and cost recovery for the test (lack of billing code) is not 
possible in the United States.  
A number of centers in Europe have experience using LCI in clinical care. At these centers, 
MBW is performed on at least an annual basis; however, MBW may be performed more often if the 
physician is unclear about symptomatology and/or if symptoms are being reported by the patient or 
parents (weight deviation, loss of appetite, fatigue, irritability). Currently, an increase of 1 unit in the LCI 
value is considered a sign of deterioration in these centers (36, 37). The medical history coupled with the 
LCI values is used as part of the clinical decision making for these patients. The overall goal is to keep 
LCI stable; patients with an increase in LCI values of more than 1 unit are often subjected to a 
modification in treatment or more aggressive investigations to understand the underlying cause for 
deterioration.  
Current Challenges to Implementing MBW Testing in Routine Care  
Implementation of MBW into routine clinical care presents several challenges, including 
equipment standardization, testing logistics in the clinical setting, staff training, cost, regulatory issues, 
and interpretation of data. These specific issues are highlighted below.  
Although Food and Drug Administration-approved devices are available that perform the MBW 
technique, validation has not been established to the same degree in the different systems (i.e., preschool 
age range). Furthermore, measurements from one system are not necessarily comparable to other systems. 
Also, offline analysis is still undertaken for some systems. These factors alone significantly limit the 
ability to routinely perform the test in the clinical setting.  
No one device has addressed all of the necessary validation and quality-control issues to 
recommend its routine use for clinical practice. Table 1 summarizes the evidence available in the different 
systems. Furthermore, training is critical for implementation into routine clinical care. As reported 
previously for infant lung function testing (53), obtaining good quality data for novel procedures is often 
challenging, especially in inexperienced centers, but can be effective with ongoing quality assurance (54).  
Finally, and perhaps of greatest importance, no published data are available outlining the 
usefulness of MBW in clinical practice. Currently, few centers have incorporated MBW into the routine 
clinical setting, and therefore longitudinal data are limited. In particular, it is unclear what change in LCI 
constitutes a minimally important clinical difference. The absence of these data precludes specific 
recommendations for its use in the clinical setting.  
Priorities for Future Research to Support Clinical Use  
More evidence is needed regarding the usefulness of LCI for clinical decision making, and 
clinically meaningful changes in LCI need to be defined. MBW indices may be ideally suited for early 
detection of peripheral airway obstruction but may not be the ideal test when more central airway 
obstruction is evident. Further data are needed to understand the limitations in interpretation of LCI and 
its role in the armamentarium of clinical pulmonary function tests.  
Conclusions  
It was the unanimous consensus of the expert panel convened that advancements in technology 
and commercialization have launched MBW as a potential outcome measure for use in CF clinical trials 
in preschool-aged patients and in patients with FEV1 in the normal range. Gaps in knowledge about the 
choice of device, gas, and standardization across systems are key issues leading the committee to 
conclude that MBW is not ready for use as a clinical trial end point in infants. Furthermore, despite the 
level of evidence available, the panel also recommended further work must be done before recommending 
the use of LCI or MBW parameters in the management of clinical care of patients with CF. Table 2 
provides a summary of the panel recommendations.  
There are still a few key areas outlined in this report that need further work. Ongoing 
collaborative efforts at a number of centers and organizations across the globe should in the near term 
provide the required information to produce a robust set of standard operating procedures, normative data, 
and recommendations for the implementation of MBW in the research setting. As future studies using 
commercial MBW in the research arena expand and more patients are studied, it is imperative that there is 
a systematic collection and analysis of clinical data to relate to MBW parameters. This type of concerted 
collaborative effort will enable the development of recommendations for the use of MBW in the clinical 
setting in the near future.  
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Table 1. Current commercially available multiple-breath washout devices in North America 
 
    Innovision Innocor  Eco Medics AG Exhalyzer D Ndd EasyOne Pro 
 
Overall design of setup Closed, rebreathing circuit 
wash-in designed with 
CO2 scrubber to prevent 
CO2 accumulation. Open 
circuit washout design. 
Open circuit wash-in and 
washout design using 
bias ﬂow. 
Open circuit washout design 
using bias ﬂow. 
Self-contained, portable Semiportable, requires 
computer 





Bias ﬂow gas mixture used Wash-in gas available as 
licensed SF6 gas 
mixture supplied by 
Innovision. 
Medical air and 100% O2 
required for N2 based 
MBW. 
Wash-in SF6/O2/N2 
mixture for SF6-based 
MBW sourced by 
individual user from local 
supplier. 
Medical air and 100% O2 




for younger age 
No online analysis available 
at present. 
Online analysis and 
quality- control features 
limited. 
Online analysis and quality- 
control features limited. 
grous No incentive software 
at present. 
Incentive software available. No incentive software at 
present. 
Suitability of software and 
equipment for the 





Suitability of software 
and equipment for 
infant age range. 
Applicable lung model FRC 
validation as yet not 
available. 
Equipment VD must be 




Current rebreathing setup not 
suitable for infants. 
Applicable lung model N2 
MBW FRC validation 
published. 
Equipment VD must be 
reduced for preschoolers. 
Current mainstream SF6 
MBW method not 
validated beyond infancy. 
Lung model N2 MBW FRC 
validation not available for 
infant range. 
Effect of 100% O2 on MBW 
results in this age group 
needs to be addressed. 
SF6 mainstream MBW 
method validated for FRC 
measurement in infants 
only. 
Applicable lung model FRC 
validation as yet not available. 
Equipment VD must be 




Lung model N2 MBW FRC 
validation not available for 
infant range. 
Effect of 100% O2 on MBW 
results in this age group 
needs to be addressed. 
Published reference data Not available Robust reference data 
not published to date.* 
Robust reference data not 
published to date.* 
 
Definition of abbreviation: MBW = multiple-breathing washout. 
*At the time of publication. 
Figure 1. Schematic representation of two washout phase tests using the two techniques. (A)N2-based setup. During 
the N2 washout, 100% oxygen is delivered using a bias ﬂow. The blue tracing shows the decay in the N2 signal 
during expiration. (B) Extrinsic gas, SF6-based setup. The green tracing shows the decay in the SF6 concentration 
during the washout-phase. R/A = room air. 
 
